Free PSA Ratio: What It Means & Why It Matters for Prostate Cancer
- What is free PSA vs. bound PSA?
- What is the free PSA ratio (percent free PSA)?
- Why is free PSA useful?
- Free PSA normal ranges and risk stratification
- When is free PSA testing indicated?
- How to interpret free PSA results
- Free PSA and the biopsy decision
- Limitations of free PSA testing
- Other biomarkers (PHI, 4Kscore, MRI)
- Interactive FAQ – 9 questions about free PSA ratio
What is free PSA vs. bound PSA?
PSA (prostate‑specific antigen) circulates in the blood in two forms:
- Free PSA (fPSA): PSA that is not attached to any protein. It floats freely in the bloodstream.
- Bound PSA (cPSA – complexed PSA): PSA that is attached (bound) to proteins, primarily alpha‑1‑antichymotrypsin (ACT) and alpha‑2‑macroglobulin.
In healthy men and men with BPH, a higher proportion of total PSA is free. In men with prostate cancer, a higher proportion is bound. This difference is the basis for the free PSA test.
What is the free PSA ratio (percent free PSA)?
The free PSA ratio (also called percent free PSA or %fPSA) is calculated as:
% Free PSA = (Free PSA / Total PSA) × 100
For example:
- Total PSA = 6.0 ng/mL
- Free PSA = 1.2 ng/mL
- % Free PSA = (1.2 / 6.0) × 100 = 20%
The result is expressed as a percentage. Higher percentages suggest benign disease (BPH); lower percentages suggest cancer.
Why is free PSA useful?
The total PSA test alone cannot distinguish between prostate cancer and benign conditions (BPH, prostatitis). This is a major problem because 70‑80% of men with elevated PSA (4‑10 ng/mL) do NOT have cancer.
Free PSA helps solve this problem by providing additional information:
- Low % free PSA (<10‑15%): Suggests higher likelihood of prostate cancer.
- High % free PSA (>25%): Suggests BPH (benign enlargement).
Using free PSA, urologists can reduce unnecessary biopsies by 20‑40% while still detecting most clinically significant cancers.
Free PSA normal ranges and risk stratification
There is no single "normal" free PSA level – it is always interpreted relative to total PSA. The following risk stratification is widely used for men with total PSA between 4‑10 ng/mL:
| % Free PSA | Risk of Prostate Cancer | Recommendation |
|---|---|---|
| <10% | High (40‑56%) | Biopsy strongly recommended |
| 10‑15% | Moderate‑High (25‑35%) | Biopsy recommended |
| 15‑20% | Moderate (15‑25%) | Consider biopsy based on other factors |
| 20‑25% | Low‑Moderate (8‑15%) | Consider observation or repeat PSA |
| >25% | Low (<8%) | Biopsy often avoidable; monitor |
Important: These risk estimates vary by age, race, and prostate size. African‑descent men may have lower % free PSA even without cancer.
When is free PSA testing indicated?
Free PSA is not a routine screening test for all men. It is typically used in specific clinical scenarios:
- Total PSA in the "grey zone" (4‑10 ng/mL): Most common indication. Helps decide whether biopsy is needed.
- Total PSA 2.5‑4 ng/mL in high‑risk men: Some guidelines suggest free PSA can help decide biopsy in younger men or those with family history.
- Prior negative biopsy but persistently elevated PSA: Free PSA can help determine if repeat biopsy is warranted.
- PSA velocity or density is concerning: Free PSA adds additional information.
Free PSA is not useful when total PSA is very high (>10 ng/mL) – biopsy is already indicated regardless of free PSA. It is also not useful when total PSA is very low (<2.5 ng/mL) – cancer risk is already low.
How to interpret free PSA results
Here are clinical scenarios to illustrate interpretation:
Case 1: High risk for cancer
- Total PSA: 5.2 ng/mL
- Free PSA: 0.4 ng/mL
- % Free PSA = (0.4 / 5.2) × 100 = 7.7%
- Interpretation: Very low % free PSA (<10%). High cancer risk. Biopsy recommended.
Case 2: Low risk for cancer
- Total PSA: 6.8 ng/mL
- Free PSA: 1.9 ng/mL
- % Free PSA = (1.9 / 6.8) × 100 = 28%
- Interpretation: High % free PSA (>25%). Low cancer risk. Biopsy can be deferred. Likely BPH.
Case 3: Borderline
- Total PSA: 4.5 ng/mL
- Free PSA: 0.7 ng/mL
- % Free PSA = (0.7 / 4.5) × 100 = 15.5%
- Interpretation: Intermediate risk (15‑20%). Consider additional markers (PHI, MRI) or repeat PSA in 3‑6 months.
Free PSA and the biopsy decision
The free PSA test helps answer the question: "Does this man with elevated PSA need a prostate biopsy?"
- % free PSA <10%: Biopsy strongly recommended (40‑56% cancer risk).
- % free PSA 10‑15%: Biopsy recommended (25‑35% cancer risk).
- % free PSA 15‑20%: Decision based on other factors (age, family history, DRE, PSA density).
- % free PSA 20‑25%: Consider deferring biopsy with repeat PSA in 3‑6 months.
- % free PSA >25%: Biopsy often avoidable (risk <8%). Monitor with repeat PSA annually.
Important nuance: Free PSA should not be the sole factor. A man with % free PSA of 22% but a suspicious DRE nodule still needs a biopsy. Conversely, a man with % free PSA of 8% but a normal DRE and low PSA density might choose active surveillance.
Limitations of free PSA testing
Free PSA is a valuable tool, but it has significant limitations:
- Does not eliminate all unnecessary biopsies: Even with % free PSA >25%, 5‑8% of men still have cancer.
- Misses some cancers: Some aggressive cancers produce normal % free PSA levels (false negatives).
- Affected by prostate size: Men with very large prostates (BPH) may have falsely low % free PSA (more bound PSA from BPH tissue).
- Affected by medications: 5‑alpha reductase inhibitors (finasteride, dutasteride) increase % free PSA (by lowering total PSA more than free). This can lead to false reassurance.
- Not standardised across labs: Different assays may produce slightly different results.
- Requires additional blood draw: Not automatically included with total PSA – must be ordered separately.
Other biomarkers (PHI, 4Kscore, MRI)
Free PSA is just one of several markers available today. Newer options include:
- Prostate Health Index (PHI): Combines total PSA, free PSA, and proPSA into a single score. More accurate than % free PSA alone. PHI >55 suggests higher cancer risk.
- 4Kscore: Combines total PSA, free PSA, intact PSA, and human kallikrein‑2 (hK2) with clinical factors. Provides a percentage risk of aggressive cancer.
- mpMRI (multiparametric MRI): Imaging test that detects suspicious lesions. A negative MRI (PI‑RADS 1‑2) can avoid biopsy in many men, even with elevated PSA.
- SelectMDx, ExoDx, MiPS: Urine‑based molecular tests that detect cancer‑related RNA.
Many experts now prefer MRI as the first step after elevated PSA, followed by targeted biopsy of suspicious lesions. Free PSA is still useful when MRI is unavailable or contraindicated.
Interactive FAQ – Free PSA ratio
There is no single normal value. Generally, % free PSA >25% is reassuring (low cancer risk), while <10% is concerning (high cancer risk).
Low % free PSA (<10-15%) suggests a higher likelihood of prostate cancer. Biopsy is usually recommended.
High % free PSA (>25%) suggests BPH (benign enlargement) rather than cancer. Biopsy is often avoidable.
Typically when total PSA is 4-10 ng/mL (grey zone) to help decide if biopsy is needed. Also useful after negative biopsy with persistently elevated PSA.
Yes – some prostate cancers produce normal % free PSA levels (false negatives). Also, large prostates (BPH) can lower % free PSA artificially.
No – no fasting required. However, avoid ejaculation for 48 hours and DRE before the blood draw.
Finasteride/dutasteride increase % free PSA (total PSA drops more than free PSA). This can cause false reassurance – results should be interpreted with caution.
Not "better" – different purposes. Total PSA is the screening test; free PSA helps interpret borderline results and reduce unnecessary biopsies.
PHI combines total PSA, free PSA, and proPSA. It is more accurate than % free PSA alone and is FDA‑approved for prostate cancer detection.
Disclaimer: This information is for educational purposes. Free PSA testing should be interpreted by a urologist in the context of your overall risk factors. Vivekananda Hospital offers comprehensive prostate cancer screening and diagnostic services.